https://www.selleckchem.com/products/roc-325.html Colorectal cancer (CRC) is one of the most common cancers and a significant cause of tumor-related death worldwide. Traditional biomarkers, such as CEA and CA199, are not sensitive enough to provide useful information for early diagnosis and treatment and are rather used to track clinical progression of disease. There is growing evidence that microRNAs (miRNA) are potentially superior to traditional biomarkers as a promising non-invasive biomarker for the timely diagnosis, and prediction of prognosis or treatment response in management of CRC. In this review, we collected the latest studies on the dysregulation of miRNAs expression in CRC and the potential for miRNAs to serve as biomarkers. Given the limitations of miRNA as discussed in this paper, its clinical applications as a diagnostic biomarker should be limited to use in combination with other biomarkers. Further research is necessary to elucidate the clinical applications of miRNA in therapy for CRC. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.I was interested in reading the paper by Hagag A and colleagues that was published in the March 2020 edition of the Infect Disord Drug Targets [1]. Neonatal sepsis is a clinical syndrome characterized by symptoms and signs of infection in the first twenty-eight days of life. Serum thyroid, cortisol and hepcidin are affected by neonatal sepsis. The purpose of the authors was to assess the predictive value of serum thyroid hormones including free triiodothyronine (free TT3) and free tetraiodothyronine (free TT4), serum cortisol and hepcidin levels through comparison of their concentrations between normal neonates and neonates with high probable late onset sepsis. They carried out a case control study on 40 neonates with suspected high probable late onset neonatal sepsis and 40 healthy neonates matched in age and sex as a control group (group II). For patients and controls